Core Viewpoint - Gyre Therapeutics has received priority review status from China's NMPA for its New Drug Application for Hydronidone (F351), aimed at treating chronic hepatitis B-induced liver fibrosis, marking a significant milestone in the drug approval process [1][2]. Group 1: Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, focused on developing and commercializing innovative treatments for liver fibrosis, including Hydronidone [8]. - Gyre Pharmaceuticals, a majority-owned subsidiary of Gyre Therapeutics, has a pipeline that includes Hydronidone, which has shown statistically significant fibrosis regression in clinical trials [7]. Group 2: Drug Information - Hydronidone (F351) is an orally administered anti-fibrotic agent that targets liver fibrosis pathways by inhibiting TGF-β1-induced signaling, which is crucial for fibrogenesis [4]. - The drug has completed Phase 3 clinical evaluation in China for chronic hepatitis B-associated liver fibrosis, including cases of early compensated cirrhosis [5]. Group 3: Market Context - Chronic hepatitis B (CHB) infection affects approximately 254 million people globally, with a significant number developing liver fibrosis and cirrhosis, highlighting the urgent medical need for effective treatments like Hydronidone [6]. - The prevalence of CHB is particularly high in China and the United States, making the potential market for Hydronidone substantial [6]. Group 4: Regulatory Insights - The priority review designation by the NMPA was established to expedite the drug registration process for innovative therapies, allowing for faster evaluation and resource allocation [3].

Core Viewpoint - Gyre Therapeutics has received priority review status from China's NMPA for its New Drug Application for Hydronidone (F351), aimed at treating chronic hepatitis B-induced liver fibrosis, marking a significant milestone in the drug approval process [1][2]. Group 1: Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, focusing on innovative treatments for liver fibrosis, with operations in both the United States and China [1][8]. - The company holds a 69.7% equity interest in Gyre Pharmaceuticals, which is responsible for the development and commercialization of Hydronidone [7]. Group 2: Drug Information - Hydronidone (F351) is an orally administered anti-fibrotic agent that targets liver fibrosis pathways by inhibiting TGF-β1-induced signaling, which is crucial for fibrogenesis [4]. - The drug has completed Phase 3 clinical trials in China for chronic hepatitis B-associated liver fibrosis, including cases of early compensated cirrhosis [5]. Group 3: Market Context - Chronic hepatitis B (CHB) affects approximately 254 million people globally, with a significant number developing liver fibrosis and cirrhosis, highlighting the urgent medical need for effective treatments [6]. - The prevalence of CHB is particularly high in China and the United States, making the approval of Hydronidone potentially impactful for millions of patients [6]. Group 4: Regulatory Insights - The priority review designation by the NMPA was established to expedite the drug registration process for new drugs with significant clinical value, allowing for a faster review and allocation of resources [3].

Product Sales and Market Position - ETUARY® (pirfenidone) generated annual sales of $106.1 million in 2025, maintaining a leading market position in the treatment of pulmonary fibrosis [32]. - Etorel® (nintedanib) was launched in June 2025 and generated $4.6 million in sales in 2025, expanding treatment options for patients with pulmonary fibrosis [34]. - Contiva® (avatrombopag) was launched in March 2025 and generated $5.5 million in sales in 2025, targeting thrombocytopenia associated with chronic liver disease [37]. - Sales of ETUARY® reached $106.1 million in 2025, although its market share has declined due to increased competition [65]. Clinical Trials and Product Development - Hydronidone met its primary endpoint in a Phase 3 trial, with 52.85% of treated patients achieving ≥1-stage fibrosis regression at Week 52 compared to 29.84% in the placebo group (p=0.0002) [46]. - A Phase 1 clinical trial for Hydronidone in the U.S. was completed, with plans to file a U.S. IND in 2026 for a Phase 2 clinical trial in MASH-associated liver fibrosis [48]. - F573, a clinical-stage product candidate for acute liver failure, is currently in a multi-stage Phase 2 clinical trial initiated in March 2023 [54]. - A Phase 1 clinical trial of Hydronidone for MASH-Associated Liver Fibrosis showed no serious adverse events, with treatment-emergent AEs including headache (25.0%) and constipation (16.7%) [93]. - The planned Phase 2 clinical trial of Hydronidone is expected to be initiated in 2026, pending regulatory feedback from the U.S. FDA [94]. - A Phase 3 trial of pirfenidone for the treatment of PD in China enrolled 272 patients across 18 clinical research centers [99]. - The Phase 1 clinical trial of F573 evaluated doses from 0.5 mg/kg to 2.0 mg/kg, with no evidence of drug accumulation observed [101]. - The Phase 2 clinical trial of F573 is designed in three stages, with the first stage completed in December 2024 [102]. Market Trends and Prevalence - The prevalence of Idiopathic Pulmonary Fibrosis (IPF) in China increased from 89,144 patients in 2018 to 161,000 patients in 2024, with a CAGR of 10.24% [63]. - The total market size of IPF in China grew from $23.9 million in 2018 to $196.1 million in 2024, reflecting a CAGR of 42% [63]. - The prevalence of Chronic Obstructive Pulmonary Disease (COPD) is significant, with a need for treatments that may slow long-term disease progression [60]. - The prevalence of RILI in China increased from 69,300 patients in 2018 to 91,800 patients in 2024, with a market size expected to reach $495.6 million by 2032 [71]. - The prevalence of CHB-associated liver fibrosis globally increased from 228.9 million patients in 2018 to 272.2 million patients in 2024, with a projected market growth to $817.2 million by 2032 [73]. - The prevalence of Acute Liver Failure (ALF) in China was 42,440 patients in 2018, expected to decline to 29,020 patients by 2032, with a market size projected to be $191.1 million [83]. - The prevalence of PAH in China increased from 50,600 patients in 2018 to 61,700 patients in 2024, projected to reach 71,300 patients by 2032 [86]. - The market size of PAH in China grew from $310 million in 2018 to $400 million in 2024, expected to reach $480 million by 2032, with a CAGR of 2.28% from 2024 to 2032 [86]. - The prevalence of COPD in China rose from 103.5 million patients in 2018 to 108.4 million patients in 2024, projected to reach 118.7 million patients by 2032 [89]. - The COPD pharmaceutical market in China increased from $880 million in 2018 to $1.13 billion in 2024, expected to reach $1.62 billion by 2032, representing a CAGR of 4.66% from 2024 to 2032 [89]. Regulatory Environment - The FDA requires substantial time and financial resources for obtaining regulatory approvals, which includes preclinical and clinical trials [127]. - The NDA submission process includes a substantial application user fee unless a waiver applies [134]. - The FDA's goal is to review standard applications within ten months and priority reviews within six months after filing [137]. - The company must navigate various regulatory requirements for drug development, including compliance with Good Laboratory Practices and Good Clinical Practices [125][127]. - The FDA may grant orphan drug designation to products intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S. [146]. - Orphan drug exclusivity grants a product seven years of exclusive approval after the first FDA approval for the designated disease, preventing other applications for the same indication [147]. - Products with fast track designation can have more frequent interactions with the FDA review team and may be eligible for priority review, aiming for action within six months [141][144]. - Accelerated approval may be granted if a product shows effects on a surrogate endpoint likely to predict clinical benefit, with post-marketing studies required to verify this [142]. - Breakthrough therapy designation allows for expedited development and review for products showing substantial improvement over existing therapies [143]. - The FDA requires that any changes to approved products, including new indications, undergo prior review and approval [152]. - The FDA enforces strict regulations on marketing and promotion, allowing only claims approved in the product's labeling [155]. - Non-compliance with FDA regulations can lead to severe consequences, including product withdrawal, fines, and potential criminal penalties [156]. - The Hatch-Waxman Amendments allow for the approval of generic drugs through abbreviated new drug applications (ANDAs) once exclusivity periods for the reference listed drug expire [157][158]. - A Paragraph IV certification allows ANDA applicants to challenge existing patents, potentially delaying approval for up to 30 months if a lawsuit is initiated [160]. - The FDA allows 505(b)(2) New Drug Applications to rely on existing studies, potentially reducing the need for new clinical trials [162]. - Patent owners can apply for a patent extension of up to five years post-NDA approval, with a maximum total patent term of 14 years [164]. - Pharmaceutical companies must comply with various healthcare regulations, including the Anti-Kickback Statute and the False Claims Act, which can lead to significant penalties for violations [165][167]. - The Physician Payments Sunshine Act requires manufacturers to report payments to healthcare professionals, impacting transparency and compliance efforts [170]. Company Operations and Workforce - The company completed a business combination to acquire an indirect controlling interest in Gyre Pharmaceuticals on October 30, 2023 [123]. - As of December 31, 2025, the company has received all material permissions and approvals required for business operations, including a Drug Production License valid from August 2025 to July 2030 [213]. - The company has a dedicated in-house R&D team of 66 employees in the PRC, focusing on drug discovery, chemistry, manufacturing and control, clinical development, medical affairs, and regulatory affairs [215]. - The company is focused on addressing unmet clinical needs through cross-functional collaboration within its R&D organization [215]. - As of December 31, 2025, Gyre Pharmaceuticals had 618 total employees, with a significant portion in sales and marketing roles across the nation [206]. - The company has seven full-time employees in the United States as of December 31, 2025 [121]. - The company is headquartered in San Diego, California, and commenced operations in 2002 [123]. - Gyre Pharmaceuticals has maintained good working relationships with employees, with no material claims or labor disputes reported during the year ended December 31, 2025 [209]. - The company aims to provide competitive salary and benefits to its employees, exceeding local legal requirements [122]. Innovation and Intellectual Property - As of the date of the Annual Report, Gyre owns 18 granted patents globally and has multiple pending patent applications that are material to its business [109]. - As of December 31, 2025, the company owns four registered artwork copyrights, 28 registered software copyrights, and 65 registered trademarks in the PRC [118]. - The company emphasizes the importance of diversifying and expanding its product pipeline through both in-house R&D and external collaboration for long-term competitiveness [214]. - The company has obtained a High-tech Enterprise Certificate valid from October 2025 to October 2028, reflecting its commitment to innovation and technology [213]. - The Zhongguancun High-tech Enterprise status is valid from December 2024 to December 2027, further supporting the company's innovation strategy [213]. Compliance and Legal Risks - Coverage and reimbursement from third-party payors are critical for product acceptance, with significant uncertainty regarding reimbursement levels for approved products [182][184]. - Third-party payors increasingly challenge medical product pricing and may adopt restrictive policies that limit sales of approved products [184]. - Compliance with data privacy laws, such as HIPAA and state-specific regulations, is essential to avoid penalties and protect personal information [174][176]. - The company may face legal risks and compliance costs due to evolving privacy laws, including the California Consumer Privacy Act [179]. - The use of artificial intelligence and machine learning in operations may be subject to regulatory scrutiny regarding data bias and discrimination [180]. - Failure to comply with healthcare laws can result in civil, criminal penalties, and reputational harm, impacting overall business operations [173][181]. Legislative Impact - The Inflation Reduction Act of 2022 allows CMS to negotiate prices for high-spend drugs, with the first ten drugs announced for negotiation on August 29, 2023 [187]. - The IRA introduces an "inflation rebate" for Medicare patients, requiring drug manufacturers to pay rebates if prices increase faster than inflation, effective from 2023 [187]. - The ACA has significantly impacted the pharmaceutical industry, including changes to Medicaid Drug Rebate calculations and the elimination of the "donut hole" in Medicare Part D starting in 2025 [192]. - The IRA's impact on commercialization and competition remains uncertain, with ongoing legislative interest in drug pricing practices [196].

分组1 - Gyre Therapeutics, Inc. reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share, representing an earnings surprise of -50.00% [1] - The company posted revenues of $37.2 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.17%, compared to year-ago revenues of $27.87 million [2] - Gyre Therapeutics has surpassed consensus revenue estimates two times over the last four quarters [2] 分组2 - The stock has added about 18% since the beginning of the year, while the S&P 500 has declined by 1% [3] - The current consensus EPS estimate for the coming quarter is $0.09 on $44.5 million in revenues, and $0.27 on $162 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Financial Performance - Full-year 2025 revenue increased by 10.2% year-over-year to $116.6 million, driven by sales growth in new products [11][10] - Fourth quarter 2025 revenue was $37.2 million, representing a 33.3% increase compared to $27.9 million in the same period of 2024 [10] - The company expects 2026 revenue guidance of $100.5 million to $111.0 million, indicating a decline of approximately 4.8% to 13.8% compared to 2025 [15][16] Product Development and Pipeline - The company completed patient enrollment in a 52-week Phase 3 trial for pirfenidone in pneumoconiosis, involving 272 patients across 18 sites [2][9] - An agreement was reached to acquire Cullgen, enhancing the company's capabilities in targeted protein degradation and expanding its pipeline [6][2] - The company plans to submit a New Drug Application (NDA) for Hydronidone in the first half of 2026, following alignment with China's Center for Drug Evaluation [2][4] Sales and Marketing - Sales of ETUARY (pirfenidone) reached $106.1 million for the full year 2025, slightly up from $105.0 million in 2024 [4] - The launch of new products, Etorel and Contiva, contributed $4.6 million and $5.5 million in sales, respectively, for the full year 2025 [4][11] - Selling and marketing expenses for the fourth quarter of 2025 were $23.8 million, a 40.8% increase from $16.9 million in the same period of 2024, primarily due to expanded commercial activities [10] Research and Development - Research and development expenses for the full year 2025 were $13.7 million, up from $12.0 million in 2024, driven by increased clinical trial costs [14][12] - The company anticipates conducting a hepatic impairment study under its active U.S. IND application to inform dose selection for Hydronidone [9][2] - The company is also preparing for an adaptive Phase 2/3 trial in China for pirfenidone targeting radiation-induced lung injury [9][2] Corporate Updates - As of December 31, 2025, the company had cash and cash equivalents totaling $75.9 million [7] - The acquisition of Cullgen is expected to close in the second quarter of 2026, creating a fully integrated biopharmaceutical company with capabilities in both the U.S. and China [6][2] - The company has aligned with China's CDE on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval [2][4]

Revenue Performance - Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range[1] - Full year 2026 revenue guidance is set at $100.5 to $111.0 million, representing a decline of approximately 13.8% to 4.8% compared to 2025[15] - Sales of ETUARY® reached $106.1 million for the full year 2025, compared to $105.0 million in 2024[5] - Revenues for Q4 2025 were $37.2 million, a 33.5% increase from $27.9 million in Q4 2024[30] - Total revenues for the year 2025 reached $116.6 million, up 10.4% from $105.8 million in 2024[30] Expenses and Financials - Selling and marketing expenses for the full year 2025 were $65.2 million, an increase of $7.7 million or 13.4% year-over-year[14] - Research and development expenses for the full year 2025 totaled $13.7 million, up from $12.0 million in 2024[14] - Operating expenses for Q4 2025 were $37.1 million, compared to $27.2 million in Q4 2024, reflecting a 36.4% increase[30] - Net income for the full year 2025 was $9.9 million, down from $17.9 million in 2024, a decrease of $8.0 million[17] - The company reported a net loss of $1,366 million for the three months ended December 31, 2025, compared to a net income of $569 million for the same period in 2024[34] - For the full year 2025, the company reported a net loss of $9,880 million, down from a net income of $17,898 million in 2024[34] - Non-GAAP adjusted net income for the three months ended December 31, 2025, was $4,268 million, up from $1,145 million in the prior year[34] - Non-GAAP adjusted net income for the full year 2025 was $18,886 million, compared to $16,882 million in 2024[34] - The total stock-based compensation for the full year 2025 was $7,157 million, significantly higher than $831 million in 2024[34] - The provision for income taxes for the three months ended December 31, 2025, was $1,300 million, compared to $203 million in the same period of 2024[34] - The provision for income taxes for the full year 2025 was $4,556 million, compared to $5,320 million in 2024[34] Clinical Trials and Product Development - Completed patient enrollment in the 52-week Phase 3 pirfenidone trial with 272 patients across 18 sites[4] - Hydronidone has completed Phase 3 clinical evaluation for chronic hepatitis B-associated liver fibrosis in China[21] - Hydronidone U.S. Investigational New Drug (IND) application anticipated in 2026, with NDA submission for conditional approval expected in the first half of 2026[1][2] - Gyre Pharmaceuticals is developing treatments for multiple conditions, including chronic obstructive pulmonary disease and pulmonary arterial hypertension[23] - Gyre received Breakthrough Therapy designation for Hydronidone from the NMPA CDE in March 2021[23] Acquisition and Cash Position - The company announced an agreement to acquire Cullgen for approximately $300 million, expected to close in Q2 2026[7] - Cash position as of December 31, 2025, was $75.9 million[8] - Cash and cash equivalents increased to $37.1 million in 2025 from $11.8 million in 2024[31] - Total assets grew to $166.1 million in 2025, up from $125.4 million in 2024, representing a 32.4% increase[31] Stock and Fair Value Adjustments - The gain from the change in fair value of warrants was a loss of $263 million for Q4 2025, compared to a loss of $194 million in Q4 2024[34] - The company continues to adjust its financials based on the Black-Scholes option pricing model for fair value of warrants[34] - Stock-based compensation increased significantly to $4,597 million in Q4 2025 from $567 million in Q4 2024[34]

Core Insights - Gyre Therapeutics (GYRE) has announced an agreement to acquire Cullgen, a clinical-stage biopharmaceutical company, in an all-stock transaction valued at approximately $300 million [1] - The acquisition will create a fully integrated biopharmaceutical company with capabilities in the U.S. and China, covering multiple therapeutic areas including inflammatory diseases, cancers, and pain [1] - The transaction is expected to close in early Q2 2026, pending customary closing conditions and regulatory approvals in the United States [1] Company Details - Cullgen will become a wholly owned subsidiary of Gyre following the acquisition [1] - Ping Zhang, the interim CEO and Executive Chairman of Gyre, will continue as Executive Chairman post-acquisition [1] - Dr. Ying Luo, the current CEO of Cullgen, is expected to become the President and CEO of Gyre and a member of its board of directors [1] Transaction Context - The acquisition follows the termination of Cullgen's proposed merger with Pulmatrix (PULM) [1]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 500 points on Monday [1] Company Highlights - Altimmune Inc (NASDAQ:ALT) saw a significant increase of 23.6%, reaching $4.34, following the FDA's grant of Breakthrough Therapy Designation for Pemvidutide in MASH [1] - GH Research PLC (NASDAQ:GHRS) surged by 33.8% to $17.72 after the FDA lifted the clinical hold on its Investigational New Drug Application for GH001 [2] - Vicor Corp (NASDAQ:VICR) rose by 20.7% to $141.08 [2] - Critical Metals Corp (NASDAQ:CRML) increased by 19.6% to $9.71 [2] - Kosmos Energy Ltd (NYSE:KOS) gained 19.3% to $1.06 after issuing an operational and financial update [2] - TRON Inc (NASDAQ:TRON) increased by 16.9% to $1.59 [2] - Nuscale Power Corp (NYSE:SMR) rose by 15.7% to $18.88 [2] - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) increased by 15.4% to $23.71 [2] - Rayonier Advanced Materials Inc (NYSE:RYAM) gained 14.1% to $6.68, with the appointment of Scott M. Sutton as President and CEO [2] - Aduro Clean Technologies Inc (NASDAQ:ADUR) rose by 14% to $12.05 [2] - Gyre Therapeutics Inc (NASDAQ:GYRE) increased by 12.7% to $7.67, announcing alignment with China's CDE on conditional approval pathway for hydronidone [2] - Endeavour Silver Corp (NYSE:EXK) gained 12.5% to $10.16 [2] - Allegro MicroSystems Inc (NASDAQ:ALGM) surged by 11.9% to $30.12 [2] - United States Antimony Corp (NYSE:UAMY) rose by 11.7% to $6.69 [2] - Oklo Inc (NYSE:OKLO) gained 11.5% to $86.82 [2] - Figure Technology Solutions Inc (NASDAQ:FIGR) increased by 11.3% to $48.66 [2] - Valero Energy Corp (NYSE:VLO) rose by 9.6% to $181.21 [2] - AeroVironment, Inc. (NASDAQ:AVAV) increased by 8.6% to $278.31 [2] - Coeur Mining Inc (NYSE:CDE) gained 8.5% to $19.05 [2] - Halliburton Co (NYSE:HAL) rose by 7.8% to $31.92, with U.S. energy stocks trading higher amid news of potential investments in Venezuela's oil industry [2] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 7.7% to $85.39 [2] - Slb NV (NYSE:SLB) increased by 7.4% to $43.19 [2] - Amkor Technology Inc (NASDAQ:AMKR) rose by 7.3% to $46.05, with Needham analyst Charles Shi maintaining a Buy rating and raising the price target from $37 to $50 [2]

Core Viewpoint - Gyre Therapeutics, Inc. announced that its subsidiary in China, Gyre Pharmaceuticals, completed a Pre-New Drug Application meeting with the Center for Drug Evaluation regarding Hydronidone, an anti-fibrotic therapy for chronic hepatitis B-associated liver fibrosis, indicating a positive regulatory pathway towards conditional approval in China [1][10]. Group 1: Regulatory Progress - Gyre Pharmaceuticals and the CDE reached a consensus that existing Phase 3 clinical data for Hydronidone support a conditional approval NDA submission for treating chronic hepatitis B-associated liver fibrosis, including early cirrhosis [2][10]. - The CDE indicated that Hydronidone qualifies for inclusion in China's Priority Review and Approval Program for Innovative Drugs, pending formal filing and regulatory review [2][10]. - Hydronidone received Breakthrough Therapy Designation from the NMPA in March 2021, recognizing its potential to address a serious condition with significant unmet medical need [3]. Group 2: Clinical Trial Results - Gyre reported that in its Phase 3 trial, 52.85% of treated patients achieved ≥1-stage fibrosis regression at Week 52, compared to 29.84% in the placebo group (p=0.0002), demonstrating the drug's efficacy [4]. - The trial also met a key secondary endpoint by showing improvement in liver inflammation without fibrosis progression and exhibited a favorable safety profile [4]. Group 3: Future Plans - The company plans to conduct an additional confirmatory Phase 3c trial in China to evaluate liver-related clinical outcomes, which will support the transition from conditional approval to regular approval [5]. - Gyre expects to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to data readiness and regulatory procedures [5][10]. Group 4: Market Need - Chronic hepatitis B-associated liver fibrosis represents a significant unmet medical need in China, with an estimated 60–70 million people infected with hepatitis B virus, and approximately 2.6 million diagnosed with clinically significant liver fibrosis [11]. Group 5: Company Overview - Gyre Pharmaceuticals is focused on developing innovative drugs for organ fibrosis, with Hydronidone being a structural analogue of pirfenidone, which has shown significant fibrosis regression in clinical trials [12]. - The company also has a pipeline that includes treatments for various conditions, and as of Q3 2025, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals [12].

Core Viewpoint - Gyre Therapeutics, Inc. announced that its subsidiary in China, Gyre Pharmaceuticals, has completed a Pre-New Drug Application meeting with the Center for Drug Evaluation regarding Hydronidone, a first-in-class anti-fibrotic therapy for chronic hepatitis B-associated liver fibrosis [1][10]. Group 1: Regulatory Progress - Gyre Pharmaceuticals and the CDE reached a consensus that existing Phase 3 clinical data for Hydronidone support a conditional approval NDA submission for treating chronic hepatitis B-associated liver fibrosis, including early cirrhosis [2][10]. - The CDE indicated that Hydronidone qualifies for inclusion in China's Priority Review and Approval Program for Innovative Drugs, pending formal filing and regulatory review [2][10]. - Hydronidone received Breakthrough Therapy Designation from the NMPA in March 2021, recognizing its potential to address a serious condition with significant unmet medical need [3]. Group 2: Clinical Trial Results - Gyre reported that in its Phase 3 trial, 52.85% of treated patients achieved ≥1-stage fibrosis regression at Week 52, compared to 29.84% in the placebo group (p=0.0002) [4]. - The trial also met a key secondary endpoint by demonstrating improvement in liver inflammation without fibrosis progression and showed a favorable safety profile [4]. Group 3: Future Plans - The company plans to conduct an additional confirmatory Phase 3c trial in China to evaluate liver-related clinical outcomes, supporting the potential conversion from conditional approval to regular approval [5]. - Gyre expects to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to final data readiness and regulatory procedures [5][10]. Group 4: Market Opportunity - Chronic hepatitis B-associated liver fibrosis represents a significant unmet medical need in China, with an estimated 60–70 million people infected with hepatitis B virus, and approximately 2.6 million diagnosed with clinically significant liver fibrosis [11].